Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Xeris Biopharma announces research collaboration with Horizon Therapeutics » 06:02
11/23/22
11/23
06:02
11/23/22
06:02
XERS

Xeris Biopharma

$1.27 /

-0.045 (-3.44%)

, HZNP

Horizon Therapeutics

$77.25 /

+0.505 (+0.66%)

Xeris Biopharma Holdings…

Xeris Biopharma Holdings (XERS) announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics (HZNP). Under the terms of the agreement, Xeris will use its proprietary formulation technology platform, XeriJect, to develop an ultra-concentrated, ready-to-use, subcutaneous injection of teprotumumab and Horizon will have an option to license the Xeris technology. Teprotumumab is the first and only medicine approved by the U.S. FDA for the treatment of Thyroid Eye Disease, a serious, progressive and potentially vision-threatening rare autoimmune disease. Teprotumumab-trbw is known as TEPEZZA in the United States. Xeris will receive an upfront payment, and may be entitled to receive development milestones, regulatory milestones, and sales-based milestones, as well as royalties based on future sales if the commercial license option is exercised. Specific financial terms of the agreement were not disclosed.

ShowHide Related Items >><<
XERS Xeris Biopharma
$1.27 /

-0.045 (-3.44%)

HZNP Horizon Therapeutics
$77.25 /

+0.505 (+0.66%)

XERS Xeris Biopharma
$1.27 /

-0.045 (-3.44%)

10/21/22 Jefferies
Xeris Biopharma assumed with a Buy at Jefferies
04/28/22 Craig-Hallum
Craig-Hallum bullish on Xeris Biopharma, initiates with a Buy
04/28/22 Craig-Hallum
Xeris Biopharma initiated with a Buy at Craig-Hallum
03/16/22 H.C. Wainwright
Xeris Biopharma price target lowered to $6 from $8 at H.C. Wainwright
HZNP Horizon Therapeutics
$77.25 /

+0.505 (+0.66%)

11/01/22 H.C. Wainwright
Horizon Therapeutics initiated with a Neutral at H.C. Wainwright
10/25/22 Piper Sandler
Horizon Therapeutics price target lowered to $88 from $90 at Piper Sandler
08/18/22 BofA
Horizon Therapeutics and Spirit AeroSystems removed from US 1 List at BOFA
08/04/22 BMO Capital
Horizon Therapeutics price target lowered to $117 from $145 at BMO Capital
XERS Xeris Biopharma
$1.27 /

-0.045 (-3.44%)

HZNP Horizon Therapeutics
$77.25 /

+0.505 (+0.66%)

HZNP Horizon Therapeutics
$77.25 /

+0.505 (+0.66%)

HZNP Horizon Therapeutics
$77.25 /

+0.505 (+0.66%)

Hot Stocks
Xeris Biopharma backs FY22 product revenue $105M-$110M  07:20
11/09/22
11/09
07:20
11/09/22
07:20
XERS

Xeris Biopharma

$1.50 /

-0.025 (-1.64%)

 
ShowHide Related Items >><<
XERS Xeris Biopharma
$1.50 /

-0.025 (-1.64%)

XERS Xeris Biopharma
$1.50 /

-0.025 (-1.64%)

10/21/22 Jefferies
Xeris Biopharma assumed with a Buy at Jefferies
04/28/22 Craig-Hallum
Craig-Hallum bullish on Xeris Biopharma, initiates with a Buy
04/28/22 Craig-Hallum
Xeris Biopharma initiated with a Buy at Craig-Hallum
03/16/22 H.C. Wainwright
Xeris Biopharma price target lowered to $6 from $8 at H.C. Wainwright
XERS Xeris Biopharma
$1.50 /

-0.025 (-1.64%)

Earnings
Xeris Biopharma reports Q3 EPS (16c), consensus (16c) » 07:19
11/09/22
11/09
07:19
11/09/22
07:19
XERS

Xeris Biopharma

$1.50 /

-0.025 (-1.64%)

Reports Q3 revenue…

Reports Q3 revenue $$29.73M , consensus $29.12M.

ShowHide Related Items >><<
XERS Xeris Biopharma
$1.50 /

-0.025 (-1.64%)

XERS Xeris Biopharma
$1.50 /

-0.025 (-1.64%)

10/21/22 Jefferies
Xeris Biopharma assumed with a Buy at Jefferies
04/28/22 Craig-Hallum
Craig-Hallum bullish on Xeris Biopharma, initiates with a Buy
04/28/22 Craig-Hallum
Xeris Biopharma initiated with a Buy at Craig-Hallum
03/16/22 H.C. Wainwright
Xeris Biopharma price target lowered to $6 from $8 at H.C. Wainwright
XERS Xeris Biopharma
$1.50 /

-0.025 (-1.64%)

Over a month ago
Hot Stocks
Xeris Biopharma announces results of extended Recorlev study from Sonics Study » 07:30
11/01/22
11/01
07:30
11/01/22
07:30
XERS

Xeris Biopharma

$1.61 /

-0.05 (-3.02%)

Xeris Biopharma Holding…

Xeris Biopharma Holding announced that the European Journal of Endocrinology EJE published the extended evaluation results of the SONICS study or NCT01838551,evaluating longer-term effects of levoketoconazole on cortisol levels, biomarkers of Cushing's syndrome (CS) comorbidities, clinical signs and symptoms of CS, and quality of life.1 The manuscript also reports findings from pituitary adenoma imaging in the SONICS study..."The results from this extended evaluation of the SONICS study provide important new evidence in support of Recorlev and will help inform clinicians' decisions and individualization of medical therapy for patients with endogenous CS," said Dr. Ken Johnson, Senior Vice President, Global Development and Medical Affairs at Xeris. "I would like to extend our gratitude to all the investigators, study coordinators and patients who participated in the SONICS trial program. Their contributions are integral in our mission to improve outcomes for patients with this rare, debilitating, and life-threatening condition."

ShowHide Related Items >><<
XERS Xeris Biopharma
$1.61 /

-0.05 (-3.02%)

XERS Xeris Biopharma
$1.61 /

-0.05 (-3.02%)

10/21/22 Jefferies
Xeris Biopharma assumed with a Buy at Jefferies
04/28/22 Craig-Hallum
Craig-Hallum bullish on Xeris Biopharma, initiates with a Buy
04/28/22 Craig-Hallum
Xeris Biopharma initiated with a Buy at Craig-Hallum
03/16/22 H.C. Wainwright
Xeris Biopharma price target lowered to $6 from $8 at H.C. Wainwright
XERS Xeris Biopharma
$1.61 /

-0.05 (-3.02%)

Initiation
Xeris Biopharma assumed with a Buy at Jefferies » 08:27
10/21/22
10/21
08:27
10/21/22
08:27
XERS

Xeris Biopharma

$1.24 /

+0.02 (+1.64%)

Jefferies analyst Glen…

Jefferies analyst Glen Santangelo assumed coverage of Xeris Biopharma with a Buy rating and $4 price target. Gvoke is a next-gen product for treating emergency hypoglycemia and he believes the current valuation "deeply discounts" the long-term revenue outlook, Santangelo tells investors.

ShowHide Related Items >><<
XERS Xeris Biopharma
$1.24 /

+0.02 (+1.64%)

XERS Xeris Biopharma
$1.24 /

+0.02 (+1.64%)

04/28/22 Craig-Hallum
Craig-Hallum bullish on Xeris Biopharma, initiates with a Buy
04/28/22 Craig-Hallum
Xeris Biopharma initiated with a Buy at Craig-Hallum
03/16/22 H.C. Wainwright
Xeris Biopharma price target lowered to $6 from $8 at H.C. Wainwright
XERS Xeris Biopharma
$1.24 /

+0.02 (+1.64%)

Hot Stocks
Xeris Biopharma's levothyroxine shows positive Phase 1 results » 06:06
10/20/22
10/20
06:06
10/20/22
06:06
XERS

Xeris Biopharma

$1.22 /

-0.07 (-5.43%)

Xeris Biopharma announced…

Xeris Biopharma announced topline results from its Phase 1 study of subcutaneous levothyroxine in healthy adult volunteers. Using its XeriSol technology, the company is developing a novel formulation of levothyroxine sodium to potentially mitigate many of the challenges associated with oral formulations of levothyroxine. The Phase 1 study was designed to evaluate the pharmacokinetics, dose proportionality and safety and tolerability of 600 undefined, 1200 undefined, and 1500 undefined of XP-8121 following SC administration and to evaluate the relative bioavailability of 600 undefined SC XP-8121 versus 600 undefined oral levothyroxine - Synthroid -. The company has requested a meeting with the FDA and expect feedback by the end of the year.

ShowHide Related Items >><<
XERS Xeris Biopharma
$1.22 /

-0.07 (-5.43%)

XERS Xeris Biopharma
$1.22 /

-0.07 (-5.43%)

04/28/22 Craig-Hallum
Craig-Hallum bullish on Xeris Biopharma, initiates with a Buy
04/28/22 Craig-Hallum
Xeris Biopharma initiated with a Buy at Craig-Hallum
03/16/22 H.C. Wainwright
Xeris Biopharma price target lowered to $6 from $8 at H.C. Wainwright
02/01/22 H.C. Wainwright
Xeris Biopharma price target raised to $6 from $5.40 at H.C. Wainwright
XERS Xeris Biopharma
$1.22 /

-0.07 (-5.43%)

Over a quarter ago
Earnings
Xeris Biopharma reports Q2 EPS (19c) vs. (41c) last year » 07:08
08/10/22
08/10
07:08
08/10/22
07:08
XERS

Xeris Biopharma

$1.71 /

-0.155 (-8.31%)

Reports Q2 revenue…

Reports Q2 revenue $25.31M, consensus $25.23M. "We continue to execute our growth strategy and are pleased to have posted record net revenue in the second quarter. Demand for Gvoke HypoPen remains strong and its market share continues to outpace the overall glucagon market; Keveyis reported its best quarter to date; and newly launched Recorlev is off to a great start," said Paul Edick, chairman and CEO of Xeris Biopharma. "We continue to drive education and awareness of all three products and remain confident in the long-term growth opportunity of each. Our strong performance year-to-date and expectations for the remainder of the year gives us confidence that we will achieve our guidance of net product revenue to $105 million to $120 million for the full year 2022, year-end cash balance of $90 million-$110 million and cash flow breakeven by year-end 2023."

ShowHide Related Items >><<
XERS Xeris Biopharma
$1.71 /

-0.155 (-8.31%)

XERS Xeris Biopharma
$1.71 /

-0.155 (-8.31%)

04/28/22 Craig-Hallum
Craig-Hallum bullish on Xeris Biopharma, initiates with a Buy
04/28/22 Craig-Hallum
Xeris Biopharma initiated with a Buy at Craig-Hallum
03/16/22 H.C. Wainwright
Xeris Biopharma price target lowered to $6 from $8 at H.C. Wainwright
02/01/22 H.C. Wainwright
Xeris Biopharma price target raised to $6 from $5.40 at H.C. Wainwright
XERS Xeris Biopharma
$1.71 /

-0.155 (-8.31%)

Hot Stocks
Xeris' commercialization partner for Ogluo, Tetris, to be acquired by Arecor » 07:36
08/01/22
08/01
07:36
08/01/22
07:36
XERS

Xeris Biopharma

$1.43 /

-0.005 (-0.35%)

Xeris Biopharma Holdings…

Xeris Biopharma Holdings (XERS) announced that Tetris Pharma-its commercialization partner for Ogluo in the UK, EEA, and Switzerland-will be acquired by Arecor Therapeutics (AREC), a UK-based, publicly traded, globally focused biopharmaceutical company, contingent upon a successful capital offering by Arecor Therapeutics. Under the terms of the proposed acquisition, Arecor Therapeutics has agreed to acquire Tetris Pharma and will continue to commercialize Ogluo in the UK and EEA. "We look forward to working with Arecor as our commercial partner if the proposed acquisition is completed. Arecor is a diversified and well capitalized company with a key focus on the diabetes space. Having our ready-to-use glucagon, Ogluo, commercialized in the UK and EEA by Arecor would be a very positive step forward in our view," said Paul R. Edick, Xeris' Chairman and CEO. "We are working expeditiously with Tetris and Arecor to affect a smooth transition of commercial activities and will continue to support the commercial efforts going forward." In July 2021, Xeris announced an exclusive agreement with Tetris Pharma Limited for the commercialization of Ogluo in the European Economic Area, United Kingdom, and Switzerland for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. Under the terms of the applicable agreements, Xeris is responsible for product supply and Tetris is responsible for the commercialization of Ogluo in the Territory. Tetris Pharma has, conditional upon completion of the Acquisition, entered into an amendment to its exclusive 16-year minimum term license and supply agreements with Xeris for the sale and distribution of Ogluo in the EEA, UK, and Switzerland. Pursuant to the license, a mid-single-digit royalty on net sales is payable to Xeris over the license period. In addition, further one-off commercial milestone payments are payable to Xeris in the event that net revenues exceed pre-defined targets in any single calendar year.

ShowHide Related Items >><<
XERS Xeris Biopharma
$1.43 /

-0.005 (-0.35%)

XERS Xeris Biopharma
$1.43 /

-0.005 (-0.35%)

04/28/22 Craig-Hallum
Craig-Hallum bullish on Xeris Biopharma, initiates with a Buy
04/28/22 Craig-Hallum
Xeris Biopharma initiated with a Buy at Craig-Hallum
03/16/22 H.C. Wainwright
Xeris Biopharma price target lowered to $6 from $8 at H.C. Wainwright
02/01/22 H.C. Wainwright
Xeris Biopharma price target raised to $6 from $5.40 at H.C. Wainwright
XERS Xeris Biopharma
$1.43 /

-0.005 (-0.35%)

Earnings
Xeris Biopharma sees FY22 revenue $105M-$120M, consensus $113.87M  07:08
05/11/22
05/11
07:08
05/11/22
07:08
XERS

Xeris Biopharma

$1.79 /

-0.055 (-2.99%)

 
ShowHide Related Items >><<
XERS Xeris Biopharma
$1.79 /

-0.055 (-2.99%)

XERS Xeris Biopharma
$1.79 /

-0.055 (-2.99%)

04/28/22 Craig-Hallum
Craig-Hallum bullish on Xeris Biopharma, initiates with a Buy
04/28/22 Craig-Hallum
Xeris Biopharma initiated with a Buy at Craig-Hallum
03/16/22 H.C. Wainwright
Xeris Biopharma price target lowered to $6 from $8 at H.C. Wainwright
02/01/22 H.C. Wainwright
Xeris Biopharma price target raised to $6 from $5.40 at H.C. Wainwright
XERS Xeris Biopharma
$1.79 /

-0.055 (-2.99%)

XERS Xeris Biopharma
$1.79 /

-0.055 (-2.99%)

XERS Xeris Biopharma
$1.79 /

-0.055 (-2.99%)

Earnings
Xeris Biopharma reports Q1 EPS (25c), consensus (25c) » 07:07
05/11/22
05/11
07:07
05/11/22
07:07
XERS

Xeris Biopharma

$1.79 /

-0.055 (-2.99%)

Reports Q1 revenue…

Reports Q1 revenue $22.1M, consensus $23.59M.

ShowHide Related Items >><<
XERS Xeris Biopharma
$1.79 /

-0.055 (-2.99%)

XERS Xeris Biopharma
$1.79 /

-0.055 (-2.99%)

04/28/22 Craig-Hallum
Craig-Hallum bullish on Xeris Biopharma, initiates with a Buy
04/28/22 Craig-Hallum
Xeris Biopharma initiated with a Buy at Craig-Hallum
03/16/22 H.C. Wainwright
Xeris Biopharma price target lowered to $6 from $8 at H.C. Wainwright
02/01/22 H.C. Wainwright
Xeris Biopharma price target raised to $6 from $5.40 at H.C. Wainwright
XERS Xeris Biopharma
$1.79 /

-0.055 (-2.99%)

XERS Xeris Biopharma
$1.79 /

-0.055 (-2.99%)

XERS Xeris Biopharma
$1.79 /

-0.055 (-2.99%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.